Novel n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
The present invention relates to compounds of Formula I, which are novel N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines and their pharmaceutically acceptable solvates. The compounds of Formula I are selective antagonists to neurokinin-3 receptor (NK-3) and are useful as therapeutic compounds. The present invention also relates to pharmaceutical compositions comprising a compound of Formula I or a pharmaceutically acceptable solvate thereof, and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant. The present invention also relates to the use of the compounds of Formula I in the manufacture of a medicament for use in treating and/or preventing various conditions, including hot flashes, or for use as a lowering agent of the circulating luteinizing hormone (LH) levels.
